Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07203833

Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
144 (estimated)
Sponsor
Centre Hospitalier Universitaire, Amiens · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Septic shock is the most severe form of infection. Currently, an early specific biomarker for septic shock is needed. Remember that shock situations are numerous, not only septic (eg hemorrhagic, cardiogenic...), and also accompanied by a severe pro-inflammatory state that it is sometimes difficult to distinguish from a septic state. Procalcitonin (PCT) is the most studied biomarker but still lacks sensitivity (77%) and specificity (79%). The investigators hypothesize that the Vasn could become this potential new biomarker and would allow a better diagnosis and thus the need or not to treat patients with antibiotics. The laboratory studies suggest a link between Vasn and septic shock. The goal of this project is to measure and compare plasma Vasn concentrations in 2 groups of patients = group 1: septic shock versus group 2: non-septic shock. Briefly, shock is defined as low blood pressure requiring vasopressor agents with confirmed infection (group 1) or without suspected infection such as patients admitted in intensive care unit post cardiac surgery with CBP (group 2). The investigators will also assess patient 28-day mortality to identify Vasn as a potential prognostic biomarker.

Conditions

Interventions

TypeNameDescription
BIOLOGICALblood sampleblood sample in order to measure the concentrations of circulating Vasn

Timeline

Start date
2025-10-19
Primary completion
2027-04-01
Completion
2027-05-01
First posted
2025-10-02
Last updated
2026-01-07

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT07203833. Inclusion in this directory is not an endorsement.